Literature DB >> 23052966

[Central pain processing and Parkinson's disease. Epidemiology, physiology, and experimental results issuing pain processing].

J A Priebe1, P Rieckmann, S Lautenbacher.   

Abstract

Parkinson's disease (PD) is caused by degeneration of the dopaminergic neurons in the substantia nigra (SN) and a resulting dysfunction of the nigrostriatal pathways including the basal ganglia. Beside motor symptoms, different types of pain (e.g., dystonic musculoskeletal pain or central pain) occur in a considerable number of patients. In addition, abnormalities in pain processing have been observed in PD patients, which may present as increased pain sensitivity. The pathophysiological mechanisms involved in disturbed pain processing of PD, however, are still poorly understood. The present article gives an overview of the relevant experimental studies, investigating the abnormalities of pain processing in PD by means of electrophysiological [electroencephalography (EEG), sympathetic skin response (SSR)] and psychophysical methods [quantitative sensory testing (QST), RIII reflex threshold]. Based on a review of the literature, it is postulated that dysfunction in endogenous pain inhibition caused by dopaminergic deficiency in the basal ganglia, especially in the striatum, but also in mesolimbic areas is a main pathophysiological mechanism involved in nociceptive abnormalities in PD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23052966     DOI: 10.1007/s00482-012-1222-9

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  31 in total

Review 1.  The role of dopamine in the nucleus accumbens in analgesia.

Authors:  N Altier; J Stewart
Journal:  Life Sci       Date:  1999       Impact factor: 5.037

Review 2.  Pain in Parkinson's disease.

Authors:  Blair Ford
Journal:  Mov Disord       Date:  2010       Impact factor: 10.338

3.  Inhibitory effects of substantia nigra on impulse transmission from nociceptors.

Authors:  Charles D Barnes; Simon J Fung; William L Adams
Journal:  Pain       Date:  1979-04       Impact factor: 6.961

4.  Association and dissociation between laser-evoked potentials and pain perception.

Authors:  L García-Larrea; R Peyron; B Laurent; F Mauguière
Journal:  Neuroreport       Date:  1997-12-01       Impact factor: 1.837

5.  Hyperalgesia and laser evoked potentials alterations in hemiparkinson: evidence for an abnormal nociceptive processing.

Authors:  Michele Tinazzi; Serena Recchia; Sara Simonetto; Giovanni Defazio; Stefano Tamburin; Giuseppe Moretto; Antonio Fiaschi; Roberto Miliucci; Massimiliano Valeriani
Journal:  J Neurol Sci       Date:  2008-10-26       Impact factor: 3.181

6.  Effect of levodopa on pain threshold in Parkinson's disease: a clinical and positron emission tomography study.

Authors:  Christine Brefel-Courbon; Pierre Payoux; Claire Thalamas; Fabienne Ory; Isabelle Quelven; François Chollet; Jean Louis Montastruc; Olivier Rascol
Journal:  Mov Disord       Date:  2005-12       Impact factor: 10.338

7.  Diffuse noxious inhibitory controls (DNIC). I. Effects on dorsal horn convergent neurones in the rat.

Authors:  Daniel Le Bars; Anthony H Dickenson; Jean-Marie Besson
Journal:  Pain       Date:  1979-06       Impact factor: 6.961

8.  Quantitative measurement of pain sensation in patients with Parkinson disease.

Authors:  R Djaldetti; A Shifrin; Z Rogowski; E Sprecher; E Melamed; D Yarnitsky
Journal:  Neurology       Date:  2004-06-22       Impact factor: 9.910

Review 9.  Brainstem interactions with the basal ganglia.

Authors:  Peter Redgrave; Véronique Coizet
Journal:  Parkinsonism Relat Disord       Date:  2007       Impact factor: 4.891

10.  Uniform inhibition of dopamine neurons in the ventral tegmental area by aversive stimuli.

Authors:  Mark A Ungless; Peter J Magill; J Paul Bolam
Journal:  Science       Date:  2004-03-26       Impact factor: 47.728

View more
  1 in total

1.  Electroneuromyographic findings in pseudoexfoliation syndrome.

Authors:  Deniz Turgut Coban; Tuncay Cakir; Muhammet Kazim Erol; Gulsum Dogan; Berna Dogan; Meral Bilgilisoy Filiz; Naciye Fusun Toraman
Journal:  Int Ophthalmol       Date:  2017-04-12       Impact factor: 2.031

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.